MPT: ODYSSEY Ahead for ACC

ACC Conference Reporter

ACC.18 | ORLANDO, FL — Will the second big cardiovascular outcomes trial for a PCSK9 inhibitor, the ODYSSEY Outcomes trial, shore up the modest benefits seen in the first? Or will clinicians end up figuratively stuck between Scylla and Charybdis? The saga will be center stage in the opening late-breaking clinical trial session at the American College of Cardiology (ACC) meeting here on Saturday. Read More >>>



Keywords: ACC18, ACC Annual Scientific Session


< Back to Listings